The University of Ottawa Dapagliflozin in STEMI Randomized Clinical Trial
The goal of this clinical trial is to assess the safety and efficacy of SGLT2i in limiting infarct size in patients with STEMI referred for PPCI. Eligible STEMI patients enrolled into the trial will be randomized to a SGLT2i or placebo. Cardiovascular Magnetic Resonance (CMR) imaging will be used to determine the infarct size.
⁃ Patients referred for PPCI meeting the following criteria are eligible for the study:
• Ischemic chest discomfort of ≥30 minutes duration, and
• Onset of chest pain ≤12 hours prior to entry into the study, and
• One of the following High-Risk criteria on a standard 12 lead ECG:
• a. Anterior STEMI with ST-segment elevation ≥2mm (0.2 mV) in each of at least 2 contiguous precordial leads (V1-V6) b. Extensive non-anterior STEMI defined as ST-segment elevation of \>1mm in two or more contiguous non-anterior leads accompanied by i. 8 or more leads with \> 1 mm ST elevation or depression, or both; OR ii. Sum of ST- segment elevation \>20mm